Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Kura Oncology Inc

NASDAQ KURA
$8.22 0.09 1.11%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 31.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
576.94M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
535.24M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
87.42M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-5.63 %

Upcoming events Kura Oncology Inc

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Kura Oncology Inc

Stock analysis Kura Oncology Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-3.17 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
1.81 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-3.25 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.25 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-49.91 -50.00

Price change Kura Oncology Inc per year

5.54$ 21.08$
Min Max

Summary analysis Kura Oncology Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Kura Oncology Inc

Revenue and net income Kura Oncology Inc

All parameters

About company Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
Address:
12730 High Bluff Drive, San Diego, CA, United States, 92130
Company name: Kura Oncology Inc
Issuer ticker: KURA
ISIN: US50127T1097
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2015-09-22
Sector: Healthcare
Industry: Biotechnology
Site: https://kuraoncology.com